于报告期内，医院业务分部营业额为人民币46.00亿元，同比轻微降低3.0%。受两年医保结算差影响，门诊和住院次均收入分别下降2.0%和8.8%。 努力通过提质增效降低次均下降对医院业务利润的影响，医院业务分部毛利为人民币9.23亿元，毛利率20.1%;医院业务分部业绩约为人民币5.21亿元，同比降低11.6%。CR Medical (01515) announced its mid-term performance in 2024, with earnings of approximately 4.976 billion yuan, a year-on-year decrease of 2.6%.
According to the CR Medical (01515) mid-term performance announcement in 2024, the earnings were approximately 4.976 billion yuan, a decrease of 2.69% compared to the previous year. The attributable net profit of the company's shareholders was approximately 0.434 billion yuan, an increase of 9.12% year-on-year. The earnings per share was 0.34 yuan, and the mid-term dividend per share was 6 cents.
As of June 30, 2024, the group manages and operates 127 medical institutions in 10 provinces and cities in China. During the reporting period, the group's own hospital outpatient and inpatient volumes were approximately 5.05 million and 280,000 respectively, representing a year-on-year growth of 3.5% and 3.0%.
During the reporting period, the operating revenue of the hospital business segment was 4.6 billion yuan, a slight decrease of 3.0% year-on-year. Due to the impact of the two-year medical insurance settlement difference, the average income per outpatient visit and per inpatient visit decreased by 2.0% and 8.8% respectively. Efforts are being made to reduce the impact of the decline in average income on the profitability of the hospital business segment by improving quality and efficiency. The gross margin of the hospital business segment was 0.923 billion yuan, with a gross margin of 20.1%. The performance of the hospital business segment decreased by 11.6% to approximately 0.521 billion yuan compared to the previous year.
